Top Story Today
A Robot Designed This Drug. Now It's in Phase III.
Insilico Medicine dosed the first patient in GENESIS-IPF-3, making rentosertib the first generative-AI-designed drug to ever reach a Phase III clinical trial. The drug targets TNIK, a master switch for lung scarring, in patients with idiopathic pulmonary fibrosis. In Phase II, patients on the drug gained 98.4 mL of lung capacity while placebo patients declined. The Phase III trial will enroll 320 patients across 47 sites over 52 weeks, and the entire AI drug discovery industry is holding its breath.
Why it matters: Over 173 AI-discovered programs are now in clinical development, but none has reached approval. If rentosertib succeeds, it validates a fundamentally new way of making medicines. If it fails, the AI drug discovery sector faces its biggest credibility crisis yet.
Read more →Clinical and Regulatory
Bayer Crashes the HER2 Lung Cancer Party With a 71% Response Rate
The FDA granted accelerated approval to Bayer's sevabertinib for HER2-mutant non-small cell lung cancer, posting a 71% confirmed response rate in patients who hadn't previously received HER2-targeted therapy. It's now the third approved option for a patient population that had zero targeted treatments just a few years ago, turning a forgotten mutation into a three-way competitive race.
Read more →The Disease With Zero Approved Treatments Might Finally Get One
The FDA accepted Roche's filing for Enspryng in MOGAD, a rare autoimmune disease that attacks the brain and spinal cord, and granted Priority Review with a January 2027 decision date. Phase III data showed a 68% reduction in relapse risk. If approved, it would be the first treatment ever cleared for MOGAD.
Read more →Novartis's $12 Billion RNA Drug Just Flopped in Phase III
Del-desiran, the RNA therapy Novartis acquired through its $12 billion Avidity Biosciences buyout, missed its primary endpoint in myotonic dystrophy type 1. The failure dragged Dyne Therapeutics down 31% in premarket trading and exposed a stubborn industry-wide problem: getting RNA drugs to actually reach muscle tissue remains unsolved.
Read more →The Itch Drug That Couldn't Scratch the Surface
Evommune's EVO756 failed its second Phase 2 trial this year, missing all endpoints in moderate-to-severe eczema after already flopping in chronic hives. Two misses effectively invalidate the MRGPRX2 target, threatening hundreds of millions in industry investment from Incyte, Septerna, and others chasing the same biology.
Read more →Deals and M&A
Novartis Pays $1.4 Billion to Fight Heart Attacks With Inflammation
Novartis is acquiring Tourmaline Bio at a 127% premium to its 60-day average, betting that blocking IL-6 (a chronic inflammatory signal) can prevent heart attacks in patients whose cholesterol is already controlled. The Phase 2 data showed up to 86% reductions in inflammatory markers, but the drug hasn't been tested in a cardiovascular outcomes trial yet.
Read more →Roche Pays $1.53 Billion for a Drug That's Never Been in a Human
Roche locked up global rights to Simcere Zaiming's trispecific antibody SIM0660, which targets three proteins on immune cells simultaneously. The $75 million upfront is a rounding error for Roche; the remaining $1.46 billion only kicks in if the preclinical asset survives clinical development. It's the latest in a wave of billion-dollar deals for Chinese-originated biotech assets.
Read more →Novartis Bets $3.2 Billion on Killing the IV Drip
Novartis signed a deal worth up to $3.22 billion with South Korea's Alteogen to convert IV infusion drugs into quick subcutaneous shots. The partnership uses Alteogen's enzyme technology to challenge Halozyme's long-standing monopoly in the subcutaneous delivery space. Which drugs Novartis plans to convert remains a mystery.
Read more →Samsung Biologics Drops $1.8 Billion on the GLP-1 Manufacturing Boom
Samsung Biologics is making an all-cash takeover bid for Swiss peptide manufacturer PolyPeptide Group at a 40% premium. The deal gives Samsung six GMP-certified sites across three continents and instant access to the exploding GLP-1 contract manufacturing market, projected to reach $68.2 billion by 2034.
Read more →Science and Innovation
The Sleep Scientists Who Might Be Headed to Stockholm
Emmanuel Mignot and Masashi Yanagisawa won the 2026 Lasker Award for discovering orexin, the brain peptide that controls wakefulness and causes narcolepsy when it's missing. 87 Lasker laureates have gone on to win the Nobel Prize, and their work spawned an entire class of insomnia drugs including Merck's Belsomra and Eisai's Dayvigo.
Read more →The Government Wants an AI Doctor for Your Heart
ARPA-H committed $62.7 million to build the first FDA-authorized AI system that can autonomously manage heart failure patients: assessing symptoms, adjusting medications, and escalating to human doctors when needed. Five teams (including Tempus AI, Stanford, and Duke) have 24 months to build it and navigate a De Novo FDA submission.
Read more →